Ashington Innovation PLC (LSE:ASHI), a special purpose acquisition company, has received the green light for its shares to trade on the Frankfurt Stock Exchange.
The firm, which aims to buy businesses primarily in the technology sector, said it was “thrilled” with the news.
Jason Smart, founder of Ashington, said: "We are thrilled to announce the listing of our shares on the Frankfurt Stock Exchange.”
“As one of the largest exchanges in the world, our dual-listing will enhance trading liquidity and facilitate investment in Ashington by institutional and retail investors across Europe."
The FSE is one of the world's largest international trading centres for securities.
Operated by the Deutsche Börse (ETR:DB1) Group, FSE is the largest of Germany's eight stock exchanges and is responsible for around 90% of all securities traded in Germany.
Last week, Ashington agreed a reverse takeover with a biotech firm less than two months after floating.
Under the non-binding terms, Ashington will acquire 100% of the total issued equity of Cell Therapy for £135 million in an all-share transaction and will also seek a £3 million fundraising to finance the drug development program and working capital.
Cell Therapy is a clinical-stage biotechnology firm with a portfolio of patented cellular medicines with a lead program that successfully completed an early-stage human clinical trial in heart failure.
Shares in Ashington were immediately suspended, pending the publication of a prospectus.